| 12.09 14:52 | dpa-AFX: Gilead: Lenacapavir Reduces HIV Infections By 96% In PURPOSE 2 Trial |
| 12.09 14:42 | dpa-AFX: *GILEAD: TWICE-YEARLY LENACAPAVIR FOR HIV PREVENTION REDUCED HIV INFECTIONS BY 96% FROM SECOND PHASE 3 CLINICAL TRIAL |
| 10.09 14:17 | dpa-AFX: Gilead Sciences To Work With Genesis To Apply AI Platform To Discover, Advance Therapies |
| 10.09 14:10 | dpa-AFX: *GENESIS SECURES $35 MLN UPFRONT FROM GILEAD |
| 10.09 14:06 | dpa-AFX: *GILEAD AND GENESIS THERAPEUTICS TO DISCOVER AND DEVELOP NOVEL, SMALL MOLECULE THERAPIES ACROSS MULTIPLE TARGETS |
| 18.08 07:44 | dpa-AFX: Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out |
| 15.08 06:03 | dpa-AFX: Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis |
| 11.08 17:21 | dpa-AFX: Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray |
| 09.08 22:06 | MÄRKTE USA/Aktien nach Vortagsrally weiter aufwärts |
| 09.08 19:02 | MÄRKTE USA/Ruhe nach Vortagesrally - Eli Lilly erneut sehr fest |
| 09.08 18:56 | MÄRKTE USA/Ruhe nach Vortagesrally - Eli Lilly erneut sehr fest |
| 09.08 16:02 | MÄRKTE USA/Geopolitik sorgt für Vorsicht |
| 09.08 15:04 | MÄRKTE USA/Wall Street mit Geopolitik im Minus gesehen |
| 08.08 22:44 | dpa-AFX: ROUNDUP: Gilead Sciences Q2 Profit Rises, Revises Full-year Guidance |
| 08.08 22:33 | dpa-AFX: Gilead Sciences Inc. Bottom Line Rises In Q2, But Misses Estimates |
| 08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 EPS $1.29 VS. $0.83 YEAR AGO |
| 08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 NET INCOME TO CO. $1.61 BLN VS. $1.05 BLN PRIOR YEAR |
| 08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 REVENUES $6.95 BLN VS. $6.60 BLN LAST YEAR |
| 08.08 12:01 | dpa-AFX: Gilead Sciences Q2 24 Earnings Conference Call At 4:30 PM ET |
| 30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
|
|
